Overview

* Alkermes ( ALKS ) Q3 revenue of $394.2 mln beats analyst expectations

* Company reports Q3 net income of $82.8 mln, diluted EPS at $0.49

* Alkermes ( ALKS ) raises 2025 financial expectations, citing strong business momentum

Outlook

* Alkermes ( ALKS ) raises 2025 revenue expectations to $1.43 bln - $1.49 bln

* Company increases 2025 VIVITROL net sales forecast to $460 mln - $470 mln

* Alkermes ( ALKS ) expects 2025 GAAP net income between $230 mln and $250 mln

Result Drivers

* PROPRIETARY PRODUCT SALES - Increased sales of LYBALVI and ARISTADA drove revenue growth, with LYBALVI sales up 32% and ARISTADA up 16% compared to Q3 2024

* MEDICAID UTILIZATION ADJUSTMENTS - Revenue growth was supported by approximately $5.0 mln for ARISTADA and $8.0 mln for VIVITROL from Medicaid utilization adjustments

* STRATEGIC INITIATIVES - Proposed acquisition of Avadel Pharmaceuticals and progress in orexin 2 receptor agonist program seen as future growth drivers

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $394.20 $355.30

Revenue mln mln (17

Analysts

)

Q3 EPS $0.49

Q3 Net $82.80

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Alkermes Plc ( ALKS ) is $45.00, about 34% above its October 27 closing price of $29.72

* The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)